Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma research hub

A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma

This study is testing a new medicine, ALE.C04, alone and with an existing drug, Pembrolizumab, for head and neck cancer that has come back or spread. It will check if the new medicine is safe and if it can help shrink the cancer.